Page 1642. In the left column, line 7, “... leading to the production of the kynurenine derivatives 3-hydroxykynurenine and 3-hydroxyanthranilic acid. These intermediates are kynurenine precursors.” should be corrected to “leading to the production of N-formylkynurenine, a precursor of kynurenine.” Page 1642. In the right column, line 13, “Incyte Corp. reported the cocrystal structure of IDO1/epacadostat” should be corrected to “Lewis-Ballester et al. reported the cocrystal structure of IDO1/epacadostat”. Page 1643. A sentence should be added to the figure legend of Figure 1: The triazolthiazole core of compound 1 was also reported by Meininger, D.; Zalameda, L.; Liu, Y.; Stepan, L. P.; Borges, L.; McCarter, J. D.; Sutherland, C. L. Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim. Biophys. Acta 2011, 1814, 1947–1954 (DOI: 10.1016/j.bbapap.2011.07.023). Page 1643. In the left column, line 29, a sentence should be added: The structure of compound 12 was reported by Mazur, I. A.; Kochergin, P. M. Studies on the imidazole series. Chem. Heterocycl. Compd. 1970, 6, 474–476 (DOI: 10.1007/BF00478395), without spectra. We collected ¹H NMR, LC–MS (ESI), HRMS (ESI) spectra and identified compound 12 as an IDO1 inhibitor in this work. Page 1658. References 23 and 30 are duplicates. This article has not yet been cited by other publications.

中文翻译：

---

独特的硫-芳香相互作用的校正有助于有效的咪唑并噻唑吲哚胺2,3-二加氧酶抑制剂的结合。

第1642页。在左栏中第7行，“ ...导致生产犬尿氨酸衍生物3-羟基犬尿氨酸和3-羟基邻氨基苯甲酸。这些中间体是犬尿氨酸的前体。” 应该更正为“导致产生N-甲酰基犬尿氨酸，一种犬尿氨酸的前体。” Page1642。在右栏的第13行，“ Incyte Corp.报告IDO1 / epacadostat的共晶体结构”应更正为“ Lewis-Ballester等人。报告了IDO1 / epacadostat的共晶体结构”。第1643页。应该在图1的图例中添加一个句子：化合物1的三唑并噻唑核心也由Meininger，D。Zalameda，L .；刘，Y ; Stepan，LP；博尔赫斯湖；麦卡特，法学博士；萨瑟兰，CL人吲哚胺2，3-二加氧酶1和2（IDO1和IDO2）的纯化和动力学表征以及选择性IDO1抑制剂的发现。Biochim。生物物理学。ACTA 2011，1814，1947年至1954年（DOI：10.1016 / j.bbapap.2011.07.023）。Page 1643.在左栏中第29行，应添加一句话：化合物12的结构由爱荷华州马祖尔; 下午，Kochergin咪唑系列的研究。化学 杂环。编译 1970年，6，474-476（DOI：10.1007 / BF00478395），无光谱。我们收集了¹ H NMR，LC-MS（ESI），HRMS（ESI）谱图，并鉴定了化合物12作为IDO1抑制剂。页面1658。参考23和30是重复的。本文尚未被其他出版物引用。